Targeting telomerase with an HLA class II-restricted TCR for cancer immunotherapy
Mol Ther (in press)
Reduced polyfunctional T cells and increased cellular activation markers in adult allergy patients reporting adverse reactions to food
BMC Immunol, 21 (1), 43
T cell receptor therapy against melanoma-Immunotherapy for the future?
Scand J Immunol, 92 (4), e12927